Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604100 | 1.00 | ALDH1A1 (0.36) | ALDH1A1HPGDHSD17B2SCD5ALOX5 | |
| SCHEMBL7609889 | 0.87 | ALDH1A1 (0.34) | ALDH1A1HPGDHSD17B2SCD5ALOX5 | |
| SCHEMBL7412352 | 0.87 | ALDH1A1 (0.34) | ALDH1A1HPGDHSD17B2SCD5ALOX5 | |
| SCHEMBL7408391 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDSCD5HDAC1PPARG | |
| SCHEMBL7452364 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDSCD5HDAC1PPARG | |
| SCHEMBL7407270 | 0.81 | ALDH1A1 (0.38) | ALDH1A1HPGDSCD5ALOX5ABCB1 | |
| SCHEMBL7407269 | 0.81 | ALDH1A1 (0.38) | ALDH1A1HPGDSCD5ALOX5ABCB1 | |
| SCHEMBL7451706 | 0.79 | ABCB1 (0.33) | ALDH1A1ABCB1HSD17B10HDAC1TMEM97 | |
| SCHEMBL7451704 | 0.79 | ABCB1 (0.33) | ALDH1A1ABCB1HSD17B10HDAC1TMEM97 | |
| SCHEMBL7407274 | 0.79 | HSD17B2 (0.34) | ALDH1A1HPGDHSD17B2SCD5ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | claimed |
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | ALDH1A1 733/4885HPGD 245/4885HSD17B2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.